{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:51:18Z","timestamp":1791899478904,"version":"4.3.4"},"reference-count":40,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Allo-SCT is a curative option for selected patients with relapsed\/refractory (R\/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3\u20134 aGVHD were associated with a higher NRM. Grade 3\u20134 aGVHD, donor type (mismatch non-related), and the time-period 2006\u20132020 were independently related to worse EFS. Patients from 1995\u20132005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R\/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.<\/jats:p>","DOI":"10.3390\/cancers14112673","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T01:40:45Z","timestamp":1653702045000},"page":"2673","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH\/GELTAMO Experience"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9062-077X","authenticated-orcid":false,"given":"Antonio","family":"Gutierrez","sequence":"first","affiliation":[{"name":"Son Espases University HospitaI, IdISBa, 07120 Palma, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9929-8617","authenticated-orcid":false,"given":"Leyre","family":"Bento","sequence":"additional","affiliation":[{"name":"Son Espases University HospitaI, IdISBa, 07120 Palma, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Novelli","sequence":"additional","affiliation":[{"name":"Hospital Sant Creu i Sant Pau, Service of Hematology, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-1028","authenticated-orcid":false,"given":"Alejandro","family":"Martin","sequence":"additional","affiliation":[{"name":"Hospital Universitario Salamanca, IBSAL, CIBERONC, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Hospital Clinic, ICMHO, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-3682","authenticated-orcid":false,"given":"Maria","family":"Queralt Salas","sequence":"additional","affiliation":[{"name":"Hospital Clinic, ICMHO, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bastos-Oreiro","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28007 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Perez","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Hernani","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6092-5393","authenticated-orcid":false,"given":"Maria","family":"Cruz Viguria","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario de Navarra, 31008 Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Lopez-Godino","sequence":"additional","affiliation":[{"name":"Hospital Morales Meseguer, 30008 Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Montoro","sequence":"additional","affiliation":[{"name":"Hospital La Fe, Facultad de Medicina, Universidad Catolica de Valencia, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8533-2562","authenticated-orcid":false,"given":"Jose","family":"Pi\u00f1ana","sequence":"additional","affiliation":[{"name":"Hospital La Fe, Facultad de Medicina, Universidad Catolica de Valencia, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Ferra","sequence":"additional","affiliation":[{"name":"ICO-IJC-Hospital Germans Trias i Pujol, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Parody","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d\u2019Oncologia (ICO), 08908 L\u2019Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9574-0383","authenticated-orcid":false,"given":"Carmen","family":"Martin","sequence":"additional","affiliation":[{"name":"Hospital Reina Sof\u00eda, 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Espa\u00f1ol","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de Arrixaca, 30120 Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrecia","family":"Ya\u00f1ez","sequence":"additional","affiliation":[{"name":"Hospital Marques de Valdecilla, IDIVAL, 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Hospital Virgen del Roc\u00edo, 41013 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joud","family":"Zanabili","sequence":"additional","affiliation":[{"name":"Hospital Asturias, 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Herrera","sequence":"additional","affiliation":[{"name":"Hospital Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-6668","authenticated-orcid":false,"given":"Maria","family":"Varela","sequence":"additional","affiliation":[{"name":"Complejo Hospital Juan Canalejo, 15006 Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Sampol","sequence":"additional","affiliation":[{"name":"Son Espases University HospitaI, IdISBa, 07120 Palma, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Caballero","sequence":"additional","affiliation":[{"name":"Hospital Universitario Salamanca, IBSAL, CIBERONC, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Grupo Espa\u00f1ol de Trasplante de Progenitores Hematopoy\u00e9ticos (GETH) and Grupo Espa\u00f1ol de Linfoma y Trasplante Aut\u00f3logo (GELTAMO)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004\u20132014: Sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): A randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma N","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"145a","DOI":"10.1182\/blood.V128.22.145.145","article-title":"Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa\/Goelams Group","volume":"128","author":"Thieblemont","year":"2016","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Hoster","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/10428194.2018.1468894","article-title":"Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: Results from a single institution study","volume":"60","author":"Faramand","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbmt.2004.09.007","article-title":"Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma","volume":"11","author":"Kasamon","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.bmt.1700989","article-title":"Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation","volume":"20","author":"Tsai","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-136158","article-title":"Safety and Preliminary Efficacy in Patients with Relapsed\/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001","volume":"136","author":"Palomba","year":"2020","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: Working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41409-017-0067-3","article-title":"Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: A retrospective study from the EBMT Lymphoma Working Party","volume":"53","author":"Robinson","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.29498","article-title":"Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"121","author":"Vaughn","year":"2015","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): A study of the British Society for Blood and Marrow Transplantation","volume":"16","author":"Cook","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/bmt.2015.156","article-title":"Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: A single-center analysis in the rituximab era","volume":"50","author":"Mussetti","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma\u2014Final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO)","volume":"93","author":"Hirt","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","article-title":"Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marr","volume":"35","author":"Gayoso","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","article-title":"Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: A comparative study of the ALWP EBMT","volume":"13","author":"Sanz","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1080\/10428190701618268","article-title":"Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma","volume":"48","author":"Gutierrez","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/bjh.14141","article-title":"Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma","volume":"174","author":"Belayachi","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s41409-020-01198-2","article-title":"Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: Results from the LyMA prospective trial","volume":"56","author":"Tessoulin","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: A multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma with Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: A multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton\u2019s Tyrosine Kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood.2019852368","article-title":"Acalabrutinib for mantle cell lymphoma","volume":"133","author":"Witzig","year":"2019","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jtct.2021.03.001","article-title":"American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies","volume":"27","author":"Munshi","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","article-title":"Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations","volume":"184","author":"Lin","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1038\/s41409-021-01418-3","article-title":"T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease","volume":"56","author":"Lew","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","article-title":"Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: A study by the EBMT Chronic Malignancies and Lymphoma Working Parties","volume":"54","author":"Dreger","year":"2019","journal-title":"Bone Marrow Transplant."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2673\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:20:19Z","timestamp":1760138419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14112673"],"URL":"https:\/\/doi.org\/10.3390\/cancers14112673","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]}}}